On January 28, 2026, Serina Therapeutics, Inc. announced that the FDA approved its IND application for SER-252, aimed at treating advanced Parkinson’s disease, enabling them to begin a Phase 1b clinical study.
AI Assistant
SERINA THERAPEUTICS INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.